Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alto Neuroscience Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ANRO
New York
8731
https://www.altoneuroscience.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alto Neuroscience Inc
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
- Apr 23rd, 2024 12:05 pm
Alto Neuroscience (ANRO): Strong Industry, Solid Earnings Estimate Revisions
- Apr 9th, 2024 1:37 pm
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
- Apr 3rd, 2024 12:05 pm
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
- Mar 21st, 2024 8:05 pm
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
- Mar 11th, 2024 12:05 pm
Alto Neuroscience to Participate in Upcoming Investor Conferences
- Mar 7th, 2024 1:00 pm
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
- Feb 27th, 2024 1:00 pm
Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- Feb 6th, 2024 9:05 pm
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
- Feb 2nd, 2024 1:57 am
Scroll